| Literature DB >> 26337218 |
Tae min You1, Kang-Hee Lee2, Soo-Hyeon Lee3, Wonse Park4.
Abstract
Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well-known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26337218 DOI： 10.1016/j.oooo.2015.07.017
Source DB: PubMed Journal: Oral Surg Oral Med Oral Pathol Oral Radiol